-
公开(公告)号:JPH0625284A
公开(公告)日:1994-02-01
申请号:JP19321592
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , BROWN PETER JONATHAN , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW , GREGSON MICHAEL , DAVIES HOWARD G
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , A61K37/64
-
公开(公告)号:NO922530A
公开(公告)日:1992-12-28
申请号:NO922530
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , A61K37/64 , C07K5/10
CPC classification number: C07K5/0222 , A61K38/00
-
公开(公告)号:ZA924758B
公开(公告)日:1993-02-24
申请号:ZA924758
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , BROWN PETER JONATHAN , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW , GREGSON MICHAEL , DAVIES HOWARD G
IPC: C07K20060101 , C07K
-
公开(公告)号:GB2295387A
公开(公告)日:1996-05-29
申请号:GB9423635
申请日:1994-11-23
Applicant: GLAXO INC
Inventor: ANDREWS ROBERT CARL , BROWN PETER JONATHAN , DEATON DAVID NORMAN , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW , GARRISON DEANNA T , MARRON BRIAN EDWARD , SMALLEY TERRENCE L , BERMAN JUDD M , NOBLE STEWART ALYWYN
IPC: C07D239/74 , C07D239/93 , C07D239/94 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D407/12 , C07D471/04 , C07D473/08 , C07D473/10 , C07D487/04 , C07D487/08 , C07D239/72 , A61K31/505
Abstract: wherein: R is selected from hydrogen, C1-6alkyl, C1-6cycloalkyl, hydroxy, C1-6alkoxy, -COO(C1-6alkyl), halogen, phenyl, phenylcarbonyl, substituted phenyl, pyridinyl, pyrimidinyl or pyrrolyl; n is 0 or 1; R is a C1-6alkylene chain optionally mono- or disubstituted independently with hydrogen, C1-6alkyl, hydroxy, C1-6alkoxy, flouro, phenyl or substituted phenyl substituents; R and R are independently selected from the group consisting of hydrogen, C1-6alkyl, hydroxy, C1-6alkoxy or halogen; and R and R are as defined in the specification; and salts thereof are useful for treating benign prostatic hyperplasia.
-
公开(公告)号:ZA9204758B
公开(公告)日:1993-02-24
申请号:ZA9204758
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , BROWN PETER JONATHAN , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW , GREGSON MICHAEL , DAVIES HOWARD G
IPC: C07K20060101 , C07K
-
公开(公告)号:NO922530L
公开(公告)日:1992-12-28
申请号:NO922530
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , C07K5/10 , A61K37/64
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
公开(公告)号:FI922964A
公开(公告)日:1992-12-28
申请号:FI922964
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
公开(公告)号:NO922530D0
公开(公告)日:1992-06-26
申请号:NO922530
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , C07K5/00
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
公开(公告)号:MX9203643A
公开(公告)日:1995-01-31
申请号:MX9203643
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , C07D209/00 , A61K31/395
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
-
-
-
-
-
-
-